GO:1900139 negative regulation of arachidonate secretion: Lipid Signaling Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900139 describes any process that stops, prevents, or reduces the frequency, rate, or extent of arachidonic acid secretion.
• Arachidonic acid is a polyunsaturated fatty acid released from membrane phospholipids and converted into eicosanoids that drive inflammation, pain, and tumor progression.
• ACSL4, FADS1, ALOX5, and STAT1-IRF1 are central genes that influence arachidonate availability and downstream secretion.
• Dysregulated arachidonate secretion is linked to colorectal cancer, triple-negative breast cancer, radiation-induced intestinal injury, and metabolic inflammation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of candidate regulators of arachidonate secretion.
• Combining lipidomics, RNA-seq, and CRISPR screening provides a rigorous path to identify and validate negative regulators of arachidonate secretion.
Description
Arachidonic acid is a conditionally essential omega-6 polyunsaturated fatty acid that serves as the precursor for prostaglandins, leukotrienes, and other eicosanoid mediators of inflammation and pain. Its release from membrane phospholipids and subsequent secretion from cells is a tightly controlled event that determines the intensity and duration of lipid mediator signaling. GO:1900139, negative regulation of arachidonate secretion, captures the biological processes that restrain this release, thereby limiting excessive eicosanoid production. Understanding this term is important because unrestrained arachidonate secretion contributes to chronic inflammatory diseases, cancer progression, and tissue injury. Recent work has shown that enzymes such as ACSL4 and FADS1, as well as transcription factors like STAT1 and IRF1, modulate arachidonic acid metabolism and secretion in disease contexts. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:1900139, its key genes, disease relevance, and experimental strategies for studying it.
negative regulation of arachidonate secretion At A Glance
| GO ID | GO:1900139 |
|---|---|
| GO term | negative regulation of arachidonate secretion |
| Ontology | biological_process |
| Synonym | down regulation of arachidonic acid secretion; down-regulation of arachidonic acid secretion; downregulation of arachidonic acid secretion; inhibition of arachidonic acid secretion; negative regulation of arachidonic acid secretion |
| Major function | Restrains the release of arachidonic acid from cells, thereby limiting eicosanoid biosynthesis and inflammatory signaling |
| Related enzymes | ACSL4, FADS1, ALOX5, and other lipid-metabolizing enzymes |
| Related transcription factors | STAT1, IRF1, FoxO1 |
| Disease relevance | Colorectal cancer, triple-negative breast cancer, radiation-induced intestinal injury, metabolic inflammation |
| Experimental models | CRISPR knockout, point-mutation, knock-in, overexpression cell models; lipidomics; RNA-seq |
What Is GO:1900139?
GO:1900139, negative regulation of arachidonate secretion, is defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate, or extent of arachidonic acid secretion. In practical terms, it encompasses molecular events that decrease the amount of free arachidonic acid released from cells, whether by limiting its liberation from membrane phospholipids, enhancing its re-esterification, or reducing its transport to the extracellular space. This regulation is critical for controlling eicosanoid-driven inflammation and maintaining lipid homeostasis.
Why Is negative regulation of arachidonate secretion Important in Cell Biology?
Negative regulation of arachidonate secretion is important because arachidonic acid is the rate-limiting precursor for a large family of bioactive eicosanoids that control inflammation, pain, vascular tone, and tumor microenvironment crosstalk. When this negative regulation fails, excessive arachidonate release can amplify inflammatory cascades and promote cancer cell survival and proliferation. Conversely, enhancing negative regulation may be therapeutically beneficial in conditions such as radiation-induced intestinal injury and metabolic inflammation. Therefore, identifying the genes and pathways that negatively regulate arachidonate secretion is a high-value research goal for both mechanistic biology and drug discovery.
• Controls the availability of arachidonic acid for prostaglandin and leukotriene synthesis.
• Limits chronic inflammation by reducing eicosanoid-driven immune cell recruitment.
• Modulates cancer progression, including colorectal cancer and triple-negative breast cancer.
• Protects against radiation-induced intestinal injury by restraining ferroptosis-associated lipid signaling.
• Influences systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B4 axis.
• Provides a mechanistic link between lipid metabolism and pain signaling.
• Offers candidate targets for anti-inflammatory and anti-tumor therapeutics.
• Enables CRISPR-based functional genomics to discover new regulators of lipid secretion.
• Supports biomarker development for diseases with dysregulated arachidonate metabolism.
• Connects endocannabinoid and arachidonate signaling in stress responses.
What Happens During negative regulation of arachidonate secretion?
Arachidonic acid liberation from membrane phospholipids
In simple terms: Arachidonic acid is first cut out of the cell membrane before it can be secreted.
Arachidonic acid is stored esterified in membrane phospholipids and is liberated by phospholipase A2 enzymes in response to cellular signals. Negative regulation of arachidonate secretion can act at this step by reducing phospholipase activity or by favoring re-esterification of free arachidonic acid back into phospholipids. ACSL4, an acyl-CoA synthetase, plays a key role in channeling arachidonic acid into lipid remodeling pathways, and its activity influences the pool of free arachidonate available for secretion.
Enzymatic conversion and eicosanoid branching
In simple terms: Once free, arachidonic acid can be converted into inflammatory messengers; blocking these conversions reduces secretion pressure.
Free arachidonic acid is oxygenated by cyclooxygenases, lipoxygenases, and cytochrome P450 enzymes to generate eicosanoids. The 5-lipoxygenase pathway, for example, produces leukotriene B4, which amplifies inflammatory signaling. Negative regulation of arachidonate secretion may indirectly limit substrate availability for these enzymes, thereby reducing eicosanoid output. FADS1, a desaturase involved in arachidonic acid synthesis, has been shown to alter arachidonic acid metabolism and intestinal microecology in colorectal cancer.
Transcriptional and signaling control of arachidonate secretion
In simple terms: Cells can turn genes on or off to adjust how much arachidonic acid they release.
Transcription factors such as STAT1 and IRF1 regulate the expression of genes involved in lipid metabolism and ferroptosis, including ACSL4. The PDK1-FoxO1 signaling axis in adipocytes controls systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B4 axis, illustrating how hormonal and metabolic signals converge on arachidonate pathways. These regulatory layers provide multiple entry points for negative regulation of arachidonate secretion.
Transport and extracellular release
In simple terms: Even after arachidonic acid is free inside the cell, it must be transported out to be secreted.
Arachidonic acid secretion requires transport across the plasma membrane, although the exact transporters remain incompletely defined. Negative regulation can occur by retaining arachidonic acid intracellularly through binding proteins or by enhancing its re-uptake. In the context of bone regeneration, neutrophil-initiated nociceptive ingrowth orchestrates inflammation resolution, suggesting that extracellular lipid mediators influence tissue repair. Astrocytes also regulate cerebral blood flow through lipid-mediated signaling, highlighting the importance of controlled arachidonate release in the brain.
Key Genes Involved in GO:1900139 negative regulation of arachidonate secretion
The following genes and proteins have been experimentally linked to arachidonic acid metabolism, secretion, or its negative regulation in published studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACSL4 | Acyl-CoA synthetase that esterifies arachidonic acid into phospholipids; involved in ferroptosis | Key target for modulating arachidonate availability and lipid peroxidation |
| FADS1 | Fatty acid desaturase involved in arachidonic acid synthesis | Alters arachidonic acid metabolism and intestinal microecology in colorectal cancer |
| ALOX5 | 5-lipoxygenase that converts arachidonic acid to leukotriene B4 | Links arachidonate secretion to inflammatory and metabolic signaling |
| STAT1 | Transcription factor that regulates IRF1 and ACSL4 expression | Mediates radiation-induced intestinal injury via ferroptosis |
| IRF1 | Transcription factor downstream of STAT1 | Part of the STAT1-IRF1-ACSL4 pathway affecting lipid metabolism |
| FoxO1 | Forkhead transcription factor regulated by PDK1 | Controls systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B4 axis |
| PDK1 | Kinase that phosphorylates and regulates FoxO1 | Upstream regulator of arachidonate-related metabolic signaling |
| PSMD14 | Deubiquitinase that stabilizes FADS1 | Targeting PSMD14 with arachidonic acid induces synthetic lethality in triple-negative breast cancer |
| CB1 receptor | Endocannabinoid receptor influenced by stress | Connects stress signaling to endocannabinoid-arachidonate pathways |
| Phospholipase A2 family | Enzymes that liberate arachidonic acid from phospholipids | Central to the initiation of arachidonate secretion |
| Cyclooxygenases | Enzymes that convert arachidonic acid to prostaglandins | Downstream effectors of arachidonate secretion |
| Cytochrome P450 enzymes | Oxidize arachidonic acid to epoxyeicosatrienoic acids | Modulate vascular and inflammatory responses |
| Neutrophil-derived mediators | Initiate nociceptive ingrowth and inflammation resolution | Link arachidonate signaling to bone regeneration |
| Astrocyte lipid signals | Regulate cerebral blood flow | Implicate arachidonate derivatives in neurovascular coupling |
How Is negative regulation of arachidonate secretion Regulated?
Negative regulation of arachidonate secretion is controlled at multiple levels. Transcriptionally, the STAT1-IRF1 axis induces ACSL4, which channels arachidonic acid into esterification and ferroptosis-related pathways, thereby influencing the free arachidonate pool. The PDK1-FoxO1 signaling axis in adipocytes modulates the 5-lipoxygenase-leukotriene B4 pathway, linking insulin sensitivity to arachidonate metabolism. Post-translational regulation of FADS1 by PSMD14 affects arachidonic acid metabolism and can be targeted for synthetic lethality in triple-negative breast cancer. Additionally, stress-related endocannabinoid-CB1 receptor signaling can influence arachidonate-derived lipid mediator release. These layers provide numerous opportunities for pharmacological or genetic intervention to enhance negative regulation of arachidonate secretion.
negative regulation of arachidonate secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FADS1 | Colorectal cancer | CRISPR knockout of FADS1 in colorectal cancer cell lines followed by lipidomics |
| PSMD14 | Triple-negative breast cancer | Point mutation or knockout of PSMD14 combined with arachidonic acid treatment |
| ACSL4 | Radiation-induced intestinal injury | Knockout of ACSL4 in intestinal epithelial cells and radiation exposure |
| FoxO1 | Metabolic inflammation and insulin resistance | Adipocyte-specific FoxO1 knockout or knock-in models |
| CB1 receptor | Stress-related disorders | CB1 knockout or overexpression in neuronal cell models |
Colorectal cancer
The FADS1-arachidonic acid axis enhances arachidonic acid metabolism and alters intestinal microecology in colorectal cancer, suggesting that negative regulation of arachidonate secretion could suppress tumor-promoting inflammation. Targeting this axis may reduce eicosanoid-driven tumor progression.
Triple-negative breast cancer
Targeting PSMD14 combined with arachidonic acid induces synthetic lethality via FADS1 m6A modification in triple-negative breast cancer, highlighting a vulnerability in arachidonate metabolism that could be exploited therapeutically. Negative regulation of arachidonate secretion may modulate this sensitivity.
Radiation-induced intestinal injury
Ferroptosis triggered by the STAT1-IRF1-ACSL4 pathway is involved in radiation-induced intestinal injury, where dysregulated arachidonate metabolism contributes to cell death. Enhancing negative regulation of arachidonate secretion might protect intestinal tissue.
Metabolic inflammation and insulin resistance
The PDK1-FoxO1 signaling in adipocytes controls systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B4 axis, linking arachidonate secretion to metabolic disease. Negative regulation of arachidonate secretion could improve insulin sensitivity.
From negative regulation of arachidonate secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase arachidonate secretion? | CRISPR knockout cell model coupled with lipidomics |
| Does a specific point mutation alter enzyme activity? | CRISPR point-mutation knock-in cell model |
| Does tagging a protein affect its localization and function? | CRISPR knock-in with fluorescent or epitope tag |
| Does overexpression of a regulator suppress secretion? | CRISPR overexpression cell model |
| Which genes negatively regulate arachidonate secretion genome-wide? | CRISPR library screening with arachidonate readout |
| How does arachidonate secretion change in disease states? | Patient-derived organoids or disease cell lines |
How to Study the negative regulation of arachidonate secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | Arachidonic acid and eicosanoid levels | Quantify secretion in CRISPR knockout cells |
| RNA-seq | Transcriptional changes in lipid genes | Identify regulators after perturbation |
| CRISPR knockout screening | Gene essentiality for arachidonate secretion | Discover novel negative regulators |
| CRISPR activation screening | Gain-of-function effects on secretion | Find suppressors of arachidonate release |
| Western blot | Protein expression of ACSL4, FADS1, etc. | Validate knockout or overexpression |
| Immunofluorescence | Subcellular localization of lipid enzymes | Assess trafficking and membrane association |
| Fluorescent fatty acid uptake assay | Arachidonic acid transport | Measure secretion and re-uptake dynamics |
| Organoid culture | Tissue-level arachidonate secretion | Model disease-relevant epithelium |
Lipidomics and arachidonic acid quantification
Mass spectrometry-based lipidomics enables direct measurement of arachidonic acid and its eicosanoid derivatives in cells and media, providing a quantitative readout of secretion. This method is essential for validating negative regulation of arachidonate secretion in CRISPR models.
RNA-seq and transcriptomic profiling
RNA sequencing can identify transcriptional changes in lipid-metabolizing enzymes such as ACSL4, FADS1, and ALOX5 following genetic perturbation. It helps link candidate regulators to the arachidonate secretion network.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens with arachidonate-responsive reporters can uncover novel negative regulators of arachidonate secretion. Hits can be validated individually using targeted knockout or overexpression.
Imaging and reporter assays
Fluorescent arachidonic acid analogs and genetically encoded lipid sensors allow real-time visualization of arachidonate release and trafficking. These assays complement biochemical measurements and provide spatial information.
How CRISPR Can Be Used to Study GO:1900139 negative regulation of arachidonate secretion
Knockout
CRISPR knockout of candidate genes such as ACSL4, FADS1, or PSMD14 allows direct testing of their role in negative regulation of arachidonate secretion. Loss-of-function clones can be analyzed by lipidomics to quantify arachidonic acid release.
Point Mutation
CRISPR point mutation can introduce specific amino acid changes in enzymes like ACSL4 or FADS1 to dissect catalytic residues or regulatory phosphorylation sites. This approach distinguishes enzymatic activity from scaffolding functions.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous loci enables tracking of protein localization and interactions under native regulation. Tagged knock-in models are valuable for studying arachidonate secretion dynamics.
Overexpression
CRISPR overexpression of candidate negative regulators can suppress arachidonate secretion and reduce eicosanoid production. This gain-of-function strategy complements knockout studies and can reveal therapeutic candidates.
How EDITGENE Supports negative regulation of arachidonate secretion Research
Researchers studying negative regulation of arachidonate secretion-related genes often need to determine whether a candidate gene is causally involved in controlling arachidonic acid release, and whether its manipulation alters disease-relevant phenotypes. EDITGENE provides end-to-end CRISPR cell model services to answer these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of arachidonate secretion research.
Frequently Asked Questions About negative regulation of arachidonate secretion
What is GO:1900139?
GO:1900139 is the Gene Ontology term for negative regulation of arachidonate secretion, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of arachidonic acid secretion.
What genes are involved in negative regulation of arachidonate secretion?
Key genes include ACSL4, FADS1, ALOX5, STAT1, IRF1, FoxO1, PDK1, and PSMD14, all of which have been linked to arachidonic acid metabolism or signaling.
How is arachidonic acid secretion regulated?
Arachidonic acid secretion is regulated by phospholipase A2 activity, re-esterification by ACSL4, transcriptional control via STAT1-IRF1 and FoxO1, and post-translational modification of enzymes like FADS1.
Why is negative regulation of arachidonate secretion important in cancer?
Excessive arachidonate secretion fuels eicosanoid-driven inflammation and tumor progression; negative regulation can suppress these effects in colorectal and breast cancers.
What diseases are associated with arachidonate secretion?
Colorectal cancer, triple-negative breast cancer, radiation-induced intestinal injury, and metabolic inflammation are associated with dysregulated arachidonate secretion.
How can I study negative regulation of arachidonate secretion in the lab?
Use CRISPR knockout or overexpression models combined with lipidomics, RNA-seq, and functional assays to measure arachidonic acid release.
What is the role of ACSL4 in arachidonate secretion?
ACSL4 esterifies arachidonic acid into phospholipids and is involved in ferroptosis, thereby influencing the free arachidonate pool available for secretion.
Does FADS1 affect arachidonic acid metabolism?
Yes, FADS1 is a desaturase that alters arachidonic acid metabolism and intestinal microecology in colorectal cancer.
Can CRISPR screening identify new regulators of arachidonate secretion?
Yes, genome-wide CRISPR knockout or activation screens with lipid readouts can uncover novel negative regulators of arachidonate secretion.
What models are best for studying arachidonate secretion?
CRISPR knockout, point-mutation, knock-in, and overexpression cell models, as well as patient-derived organoids, are suitable for studying arachidonate secretion.
Conclusion
GO:1900139, negative regulation of arachidonate secretion, represents a critical control point in lipid signaling that impacts inflammation, cancer, and metabolic disease. The integration of QuickGO annotation with verified literature highlights key genes such as ACSL4, FADS1, and PSMD14, and demonstrates how CRISPR-based models can dissect their functions. Future research using advanced lipidomics and functional genomics will likely uncover additional negative regulators and therapeutic opportunities.
References
- 1. Ding K et al.. 2023. Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism.. Chin Med J (Engl) 136(21):2521-2537 PMID: 37442770
- 2. Xu C et al.. 2023. FADS1-arachidonic acid axis enhances arachidonic acid metabolism by altering intestinal microecology in colorectal cancer.. Nat Commun 14(1):2042 PMID: 37041160
- 3. Kong P et al.. 2023. Ferroptosis triggered by STAT1- IRF1-ACSL4 pathway was involved in radiation-induced intestinal injury.. Redox Biol 66:102857 PMID: 37611494
- 4. Yu Y et al.. 2025. Targeting PSMD14 combined with arachidonic acid induces synthetic lethality via FADS1 m(6)A modification in triple-negative breast cancer.. Sci Adv 11(19):eadr3173 PMID: 40344056
- 5. Qi X et al.. 2026. Neutrophil-initiated nociceptive ingrowth orchestrates inflammation resolution to potentiate bone regeneration.. Bone Res 14(1):9 PMID: 41554692
- 6. Mishra A et al.. 2024. Astrocyte Regulation of Cerebral Blood Flow in Health and Disease.. Cold Spring Harb Perspect Biol 16(4) PMID: 38316553
- 7. Hosooka T et al.. 2020. The PDK1-FoxO1 signaling in adipocytes controls systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B(4) axis.. Proc Natl Acad Sci U S A 117(21):11674-11684 PMID: 32393635
- 8. Hillard CJ. 2014. Stress regulates endocannabinoid-CB1 receptor signaling.. Semin Immunol 26(5):380-8 PMID: 24882055
